Sun Pharmaceutical Industries has announced that USFDA has granted an approval for the Abbreviated New Drug Application (ANDA) to market generic Paraplatin , carboplatin injection.
These generic versions of carboplatin 10mg/ml injections packed in 5 ml, 15ml and 45 ml single use vials are bio-equivalent to Paraplatin injections distributed by Bristol Myers Squibb Oncology/Virology. Carboplatin injections are indicated as initial and secondary therapy in patients with advanced ovarian carcinoma.
The company made this announcement during the trading hours today, 23 September 2008.
BSE tips
No comments:
Post a Comment